Table 3.
Statistical analysis of metastatic cancer cell movements upon inhibition of actin regulators
| Protein | MSD (α) | MLE for μ | Akaike weights | ||
|---|---|---|---|---|---|
| inhibited | Truncated power law | TP | P | E | |
| Control | 1.54 ± 0.01 | 2.49 ± 0.07 | > 0.99 | < 0.01 | < 0.01 |
| Cofilin1siRNA | 1.56 ± 0.05 | 3.01 ± 0.14 | > 0.99 | < 0.01 | < 0.01 |
| Profilin1siRNA | 1.28 ± 0.01 | 2.62 ± 0.08 | > 0.99 | < 0.01 | < 0.01 |
| Dia1siRNA | 1.51 ± 0.09 | 2.57 ± 0.11 | > 0.99 | < 0.01 | < 0.01 |
| Arp2/3CK666 | 1.01 ± 0.03 | 3.27 ± 0.09 | > 0.99 | < 0.01 | < 0.01 |
| Rac1NSC23766 | 1.51 ± 0.03 | 2.51 ± 0.08 | > 0.99 | < 0.01 | < 0.01 |
| Myosin II Blebbistatin | 1.83 ± 0.09 | 1.76 ± 0.07 | > 0.99 | < 0.01 | < 0.01 |
Table summarizes α exponent values and the maximum likelihood estimates, MLEs70, of the truncated power exponents μ for all treatments (± values give the 95% confidence intervals) described in Fig. 5. For the knockdowns, the values shown correspond to 30 nM siRNA concentrations. For the chemical inhibitors data shown corresponds to: 40 μM CK666 (for Arp2/3), 100 μM NSC23755 (Rac1), 10 μM Blebbistatin (Myosin II). The additional results for all drug and siRNA concentrations tested are shown in Supplementary Figures 10–14. Notice that Arp2/3 inhibition (highlighted in bold) reverts motions to diffusive characterized by α ~ 1 and truncated power law distribution with μ > 3. Lower cutoff values were a = 6 for Control, Cofilin1, and Profilin1 siRNAs, and a = 3 for other treatments. Note that in all cases truncated power law (TP) distribution is favored over power law (P) and exponential (E) distributions, and diffusive-vs-Lévy characteristic is determined by the magnitude of the μ exponent. Analyses based on the following numbers of cells and time points: Control (n = 69 cells, m = 17,569 time points); Cofilin1siRNA (n = 25 cells, m = 7,466 time points); Profilin1 siRNA (n = 29 cells, m = 7,250 time points); Dia1 siRNA (n = 7 cells, m = 2,017 time points); Arp2/3 CK666 (n = 36 cells, m = 9,008 time points); Rac1NSC (n = 26 cells, m = 7,407 time points); Myosin IIBlebbistatin (n = 26 cells, m = 5,413 time points). See Supplementary Movies 9–12 and Supplementary Movies 16–18